270 related articles for article (PubMed ID: 21397729)
1. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C.
Backus LI; Boothroyd DB; Phillips BR; Belperio P; Halloran J; Mole LA
Clin Gastroenterol Hepatol; 2011 Jun; 9(6):509-516.e1. PubMed ID: 21397729
[TBL] [Abstract][Full Text] [Related]
2. Different viral kinetics between hepatitis C virus genotype 1 and 2 as on-treatment predictors of response to a 24-week course of high-dose interferon-alpha plus ribavirin combination therapy.
Yu ML; Chuang WL; Dai CY; Lee LP; Hsieh MY; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Tsai SL; Kuo HT
Transl Res; 2006 Sep; 148(3):120-7. PubMed ID: 16938649
[TBL] [Abstract][Full Text] [Related]
3. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus.
Berenguer J; von Wichmann MA; Quereda C; Miralles P; Mallolas J; López-Aldeguer J; Alvarez-Pellicer J; De Miguel J; Crespo M; Guardiola JM; Tellez MJ; Galindo MJ; Arponen S; Barquilla E; Bellón JM; González-García J;
J Antimicrob Chemother; 2011 Dec; 66(12):2843-9. PubMed ID: 21965432
[TBL] [Abstract][Full Text] [Related]
4. Update on the treatment of patients with non-genotype 1 hepatitis C virus infection.
Mangia A; Mottola L; Piazzolla V
Clin Infect Dis; 2013 May; 56(9):1294-300. PubMed ID: 23271787
[TBL] [Abstract][Full Text] [Related]
5. Clinical effects of viral relapse after interferon plus ribavirin in patients co-infected with human immunodeficiency virus and hepatitis C virus.
Berenguer J; Alvarez-Pellicer J; Carrero A; Von Wichmann MA; López-Aldeguer J; Mallolas J; Galindo MJ; Van Den Eynde E; Téllez MJ; Quereda C; Tural C; Sanz J; Barros C; Santos I; Pulido F; Guardiola JM; Ortega E; Rubio R; Jusdado JJ; Montes ML; Gaspar G; Barquilla E; Bellón JM; González-García J;
J Hepatol; 2013 Jun; 58(6):1104-12. PubMed ID: 23395690
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of patients with chronic hepatitis C with sustained virologic response to interferon.
Ferreira Sda C; Carneiro Mde V; Souza FF; Teixeira AC; Villanova MG; Figueiredo JF; Passos AD; Ramalho LN; Zucoloto S; Martinelli Ade L
Braz J Infect Dis; 2010; 14(4):330-4. PubMed ID: 20963315
[TBL] [Abstract][Full Text] [Related]
7. Treating hepatitis C: current standard of care and emerging direct-acting antiviral agents.
Poordad F; Dieterich D
J Viral Hepat; 2012 Jul; 19(7):449-64. PubMed ID: 22676357
[TBL] [Abstract][Full Text] [Related]
8. The number needed to treat to prevent mortality and cirrhosis-related complications among patients with cirrhosis and HCV genotype 1 infection.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Manns MP; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
J Viral Hepat; 2014 Aug; 21(8):568-77. PubMed ID: 24118177
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with HCV antiviral treatment uptake among participants of a community-based HCV programme for marginalized patients.
Charlebois A; Lee L; Cooper E; Mason K; Powis J
J Viral Hepat; 2012 Dec; 19(12):836-42. PubMed ID: 23121361
[TBL] [Abstract][Full Text] [Related]
10. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.
van der Meer AJ; Veldt BJ; Feld JJ; Wedemeyer H; Dufour JF; Lammert F; Duarte-Rojo A; Heathcote EJ; Manns MP; Kuske L; Zeuzem S; Hofmann WP; de Knegt RJ; Hansen BE; Janssen HL
JAMA; 2012 Dec; 308(24):2584-93. PubMed ID: 23268517
[TBL] [Abstract][Full Text] [Related]
11. The risk of long-term morbidity and mortality in patients with chronic hepatitis C: results from an analysis of data from a Department of Veterans Affairs Clinical Registry.
McCombs J; Matsuda T; Tonnu-Mihara I; Saab S; Hines P; L'italien G; Juday T; Yuan Y
JAMA Intern Med; 2014 Feb; 174(2):204-12. PubMed ID: 24193887
[TBL] [Abstract][Full Text] [Related]
12. Treatment of HCV reduces viral hepatitis-associated liver-related mortality in patients: An ERCHIVES study.
Butt AA; Yan P; Shaikh OS; Lo Re V; Abou-Samra AB; Sherman KE
J Hepatol; 2020 Aug; 73(2):277-284. PubMed ID: 32145260
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of chronic hepatitis C therapy with pegylated interferon and ribavirin in patients on methadone maintenance treatment.
Neukam K; Mira JA; Gilabert I; Claro E; Vázquez MJ; Cifuentes C; García-Rey S; Merchante N; Almeida C; Macías J; Pineda JA
Eur J Clin Microbiol Infect Dis; 2012 Jun; 31(6):1225-32. PubMed ID: 21971821
[TBL] [Abstract][Full Text] [Related]
14. Direct-acting antiviral sustained virologic response: Impact on mortality in patients without advanced liver disease.
Backus LI; Belperio PS; Shahoumian TA; Mole LA
Hepatology; 2018 Sep; 68(3):827-838. PubMed ID: 29377196
[TBL] [Abstract][Full Text] [Related]
15. Mortality in patients with chronic and cleared hepatitis C viral infection: a nationwide cohort study.
Omland LH; Krarup H; Jepsen P; Georgsen J; Harritshøj LH; Riisom K; Jacobsen SE; Schouenborg P; Christensen PB; Sørensen HT; Obel N;
J Hepatol; 2010 Jul; 53(1):36-42. PubMed ID: 20400197
[TBL] [Abstract][Full Text] [Related]
16. Excess liver-related morbidity of chronic hepatitis C patients, who achieve a sustained viral response, and are discharged from care.
Innes HA; Hutchinson SJ; Allen S; Bhattacharyya D; Bramley P; Delahooke TE; Dillon JF; Forrest E; Fraser A; Gillespie R; Goldberg DJ; Kennedy N; McDonald S; McLeod A; Mills PR; Morris J; Hayes P;
Hepatology; 2011 Nov; 54(5):1547-58. PubMed ID: 22045672
[TBL] [Abstract][Full Text] [Related]
17. Sustained virological response from interferon-based hepatitis C regimens is associated with reduced risk of extrahepatic manifestations.
Rossi C; Jeong D; Wong S; McKee G; Butt ZA; Buxton J; Wong J; Darvishian M; Bartlett S; Samji H; Yu A; Binka M; Alvarez M; Adu PA; Tyndall M; Krajden M; Janjua NZ;
J Hepatol; 2019 Dec; 71(6):1116-1125. PubMed ID: 31433302
[TBL] [Abstract][Full Text] [Related]
18. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
19. Therapy for hepatitis C virus infection increases survival of patients with pretreatment anemia.
Mohanty A; Erqou S; McGinnis KA; Vanasse G; Freiberg MS; Sherman KE; Butt AA
Clin Gastroenterol Hepatol; 2013 Jun; 11(6):741-7.e3. PubMed ID: 23376794
[TBL] [Abstract][Full Text] [Related]
20. Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
Simmons B; Saleem J; Heath K; Cooke GS; Hill A
Clin Infect Dis; 2015 Sep; 61(5):730-40. PubMed ID: 25987643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
